Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

HealthEquity

HQY Healthcare Unknown Updated July 20, 2026
$97.75
52W $72.76 – $105.96
61/100
36.6
0.21
Explore HQY Further
📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
AI Committee Verdict
Buy
Conviction: Contested · 57% agreement · 7 analysts
+0.6%
-8.6%
0.07:1
Contested
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is HQY Bullish or Bearish?
Bullish. Innellis AI committee rates HealthEquity (HQY) Buy with a composite score of 61/100 , based on 7 analysts with 57% agreement. Last updated July 20, 2026.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
  • RSI at or above 70 signals overbought conditions — bearish entry bias.
  • Positive MACD histogram signals bullish momentum.
  • Daily trend: uptrend.
  • Weekly trend: uptrend.
  • Daily and weekly trends are both bullish — multi-timeframe alignment, highest confidence.
Bear Case
  • RSI is overbought at 70.8 — momentum may be exhausted.
  • Risk/reward is unfavorable: 8.6% downside vs 0.6% upside.
Price History (6M)
AI Investment Committee
Committee Consensus As of July 20, 2026
Overall Committee Score
61/100
Agreement
57%
Analysts
7
Conviction
Contested
Value Analyst neutral
55 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− P/E of 35.4 is moderate-to-rich
Growth Analyst bullish
72 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 94.2% YoY
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst neutral
52 / 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
− Bollinger bandwidth of 22.0% signals elevated volatility
Macro Analyst bullish
70 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
74 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.50 across 2 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2975.52)
Open Full Terminal →
Investment Thesis Evolution

Committee score moved marginally from 61.4 to 61.4.

Analyst-level changes:
  • Portfolio Manager: +1 bearish signal(s).

Comparing 2026-07-19 to 2026-07-20 (1 day apart).

Technical Analysis
RSI (14)
70.8
Overbought
MACD Histogram
0.415
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$90.36
Resistance
$99.42
Bollinger %B
0.81
Inside Bands
Price vs Moving Averages
EMA 9
$96.24 Above
EMA 21
$93.48 Above
EMA 50
$89.85 Above
EMA 200
$88.17 Above
Fundamental Analysis
Valuation
58
Growth
93
Profitability
0
Financial Health
100
Cash Flow
37
Valuation
P/E Ratio 36.6×
P/B Ratio 4.08×
PEG Ratio 0.39
Dividend Yield 0.00%
52W High $105.96
52W Low $72.76
Quality & Growth
ROE 10.2%
ROA 6.3%
Gross Margin 72.7%
Operating Margin 25.5%
Revenue Growth YoY
Debt / Equity 0.48
AI Fundamental Assessment
P/E ratio of 36.6 (rich relative to a 15-40x range); Price-to-book of 4.1x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.1%; Net margin of 0.2%; Gross margin of 0.7%; Current ratio of 3.44 (healthy short-term liquidity); Debt-to-equity of 0.48; Free cash flow margin of 1.0% (thin cash generation); Free cash flow per share is positive (5.78); Most recent quarter beat estimates by 10.1%; 4 consecutive earnings beats; EPS growth accelerating (-5.9% -> +30.5% QoQ); Analyst estimates rising over recent quarters
Key Risks
  • RSI is overbought at 70.8 — momentum may be exhausted.
  • Risk/reward is unfavorable: 8.6% downside vs 0.6% upside.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full HQY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal → Mobile
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime